New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
PR Newswire•09/10/2026•06:45 ET
1
Key Highlights
- ➤Taltz and Zepbound produced broader biomarker responses than Taltz alone by Week 12
- ➤Week 36 showed 482 versus 140 differentially expressed proteins with combination therapy
- ➤Week 36 showed 467 versus 16 differentially expressed genes with combination therapy
- ➤Combination therapy previously delivered superior skin clearance and clinically meaningful weight reduction
- ➤TOGETHER-PsO randomized 274 adults with psoriasis and obesity or overweight comorbidities
Expert Statements
Mark Genovese, Senior Vice President of Lilly Immunology Development
“People living with psoriasis and obesity carry a compounded burden that extends beyond what is visible, yet these conditions are too often viewed through separate treatment lenses,”
Mark Genovese, Senior Vice President of Lilly Immunology Development
“The broader biomarker changes observed with Taltz and Zepbound, including those associated with skin clearance, may point to a meaningful relationship between immune and metabolic biology. Along with previously reported clinical outcomes, these findings support a more comprehensive approach to psoriasis care that also addresses obesity for people managing both conditions.”
James G. Krueger, Professor and Laboratory Head, The Rockefeller University
“This analysis provides new insights into the potential connected immune and metabolic biology in people with psoriasis and obesity,”
James G. Krueger, Professor and Laboratory Head, The Rockefeller University
“What is most compelling is these findings identified differences in inflammatory pathways when patients received concomitant treatment with Taltz plus Zepbound for both conditions. These data at the intersection of psoriasis and obesity highlight immunometabolic health as an important area for continued scientific research.”
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity PR Newswire
Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study
Get started
Create a free account to read the full story.